Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis

Objective Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lupus 2022-01, Vol.31 (1), p.97-104
Hauptverfasser: Andrade Balbi, Verena, Artur Silva, Clovis, Nascimento Pedrosa, Tatiana, Maria Rodrigues Pereira, Rosa, Maria de Arruda Campos, Lucia, Pires Leon, Elaine, Duarte, Nilo, Melechco Carvalho, Valdemir, Gofinet Pasoto, Sandra, Cordeiro do Rosário, Debora, Kolachinski Brandao, Leticia, I Brunner, Hermine, Bonfá, Eloisa, Emi Aikawa, Nadia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 104
container_issue 1
container_start_page 97
container_title Lupus
container_volume 31
creator Andrade Balbi, Verena
Artur Silva, Clovis
Nascimento Pedrosa, Tatiana
Maria Rodrigues Pereira, Rosa
Maria de Arruda Campos, Lucia
Pires Leon, Elaine
Duarte, Nilo
Melechco Carvalho, Valdemir
Gofinet Pasoto, Sandra
Cordeiro do Rosário, Debora
Kolachinski Brandao, Leticia
I Brunner, Hermine
Bonfá, Eloisa
Emi Aikawa, Nadia
description Objective Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN). Methods Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry. Results There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013). Conclusions We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off.
doi_str_mv 10.1177/09612033211062515
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2615476923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_09612033211062515</sage_id><sourcerecordid>2615476923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</originalsourceid><addsrcrecordid>eNp1kF9LwzAUxYMobk4_gC8S8MWXzvxP-yhDnTAQQZ9LmqS2I2tq0or79rZsKig-XS73d849HADOMZpjLOU1ygQmiFKCMRKEY34ApphJmQwHcgim4z0ZgQk4iXGNEKI4E8dgQlkmuEzJFDwttyb4j62unA_-ra8bCwvnvYHOvlsXYRusqXUXYelUsLBuoK5qZ6oBSXwTbQdd3_YRNratQt3V8RQclcpFe7afM_Byd_u8WCarx_uHxc0q0VSkXWIzRUyKSk4EL0zBlEBsWBEvBONCsZJTpVNBUYa5pKm2hS5MyQg1FHFEJZ2Bq51vO-a2scs3ddTWOdVY38ecCMyZFBmhA3r5C137PjRDuoEiRApGxGiId5QOPsZgy7wN9UaFbY5RPvad_-l70FzsnftiY8234qvgAZjvgKhe7c_b_x0_AcXNh00</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622764267</pqid></control><display><type>article</type><title>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Andrade Balbi, Verena ; Artur Silva, Clovis ; Nascimento Pedrosa, Tatiana ; Maria Rodrigues Pereira, Rosa ; Maria de Arruda Campos, Lucia ; Pires Leon, Elaine ; Duarte, Nilo ; Melechco Carvalho, Valdemir ; Gofinet Pasoto, Sandra ; Cordeiro do Rosário, Debora ; Kolachinski Brandao, Leticia ; I Brunner, Hermine ; Bonfá, Eloisa ; Emi Aikawa, Nadia</creator><creatorcontrib>Andrade Balbi, Verena ; Artur Silva, Clovis ; Nascimento Pedrosa, Tatiana ; Maria Rodrigues Pereira, Rosa ; Maria de Arruda Campos, Lucia ; Pires Leon, Elaine ; Duarte, Nilo ; Melechco Carvalho, Valdemir ; Gofinet Pasoto, Sandra ; Cordeiro do Rosário, Debora ; Kolachinski Brandao, Leticia ; I Brunner, Hermine ; Bonfá, Eloisa ; Emi Aikawa, Nadia</creatorcontrib><description>Objective Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN). Methods Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry. Results There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013). Conclusions We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/09612033211062515</identifier><identifier>PMID: 34965782</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Antirheumatic Agents - therapeutic use ; Blood levels ; Children ; Chromatography, Liquid ; Humans ; Hydroxychloroquine ; Hydroxychloroquine - blood ; Hydroxychloroquine - therapeutic use ; Liquid chromatography ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Lupus nephritis ; Lupus Nephritis - diagnosis ; Lupus Nephritis - drug therapy ; Mass spectroscopy ; Morbidity ; Nephritis ; Prednisone ; Systemic lupus erythematosus</subject><ispartof>Lupus, 2022-01, Vol.31 (1), p.97-104</ispartof><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</citedby><cites>FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</cites><orcidid>0000-0002-3723-5028 ; 0000-0001-9250-6508 ; 0000-0002-0520-4681 ; 0000-0002-7585-4348 ; 0000-0001-9653-0468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/09612033211062515$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/09612033211062515$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34965782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andrade Balbi, Verena</creatorcontrib><creatorcontrib>Artur Silva, Clovis</creatorcontrib><creatorcontrib>Nascimento Pedrosa, Tatiana</creatorcontrib><creatorcontrib>Maria Rodrigues Pereira, Rosa</creatorcontrib><creatorcontrib>Maria de Arruda Campos, Lucia</creatorcontrib><creatorcontrib>Pires Leon, Elaine</creatorcontrib><creatorcontrib>Duarte, Nilo</creatorcontrib><creatorcontrib>Melechco Carvalho, Valdemir</creatorcontrib><creatorcontrib>Gofinet Pasoto, Sandra</creatorcontrib><creatorcontrib>Cordeiro do Rosário, Debora</creatorcontrib><creatorcontrib>Kolachinski Brandao, Leticia</creatorcontrib><creatorcontrib>I Brunner, Hermine</creatorcontrib><creatorcontrib>Bonfá, Eloisa</creatorcontrib><creatorcontrib>Emi Aikawa, Nadia</creatorcontrib><title>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Objective Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN). Methods Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry. Results There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013). Conclusions We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off.</description><subject>Adult</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Blood levels</subject><subject>Children</subject><subject>Chromatography, Liquid</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Hydroxychloroquine - blood</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Liquid chromatography</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus nephritis</subject><subject>Lupus Nephritis - diagnosis</subject><subject>Lupus Nephritis - drug therapy</subject><subject>Mass spectroscopy</subject><subject>Morbidity</subject><subject>Nephritis</subject><subject>Prednisone</subject><subject>Systemic lupus erythematosus</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kF9LwzAUxYMobk4_gC8S8MWXzvxP-yhDnTAQQZ9LmqS2I2tq0or79rZsKig-XS73d849HADOMZpjLOU1ygQmiFKCMRKEY34ApphJmQwHcgim4z0ZgQk4iXGNEKI4E8dgQlkmuEzJFDwttyb4j62unA_-ra8bCwvnvYHOvlsXYRusqXUXYelUsLBuoK5qZ6oBSXwTbQdd3_YRNratQt3V8RQclcpFe7afM_Byd_u8WCarx_uHxc0q0VSkXWIzRUyKSk4EL0zBlEBsWBEvBONCsZJTpVNBUYa5pKm2hS5MyQg1FHFEJZ2Bq51vO-a2scs3ddTWOdVY38ecCMyZFBmhA3r5C137PjRDuoEiRApGxGiId5QOPsZgy7wN9UaFbY5RPvad_-l70FzsnftiY8234qvgAZjvgKhe7c_b_x0_AcXNh00</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Andrade Balbi, Verena</creator><creator>Artur Silva, Clovis</creator><creator>Nascimento Pedrosa, Tatiana</creator><creator>Maria Rodrigues Pereira, Rosa</creator><creator>Maria de Arruda Campos, Lucia</creator><creator>Pires Leon, Elaine</creator><creator>Duarte, Nilo</creator><creator>Melechco Carvalho, Valdemir</creator><creator>Gofinet Pasoto, Sandra</creator><creator>Cordeiro do Rosário, Debora</creator><creator>Kolachinski Brandao, Leticia</creator><creator>I Brunner, Hermine</creator><creator>Bonfá, Eloisa</creator><creator>Emi Aikawa, Nadia</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3723-5028</orcidid><orcidid>https://orcid.org/0000-0001-9250-6508</orcidid><orcidid>https://orcid.org/0000-0002-0520-4681</orcidid><orcidid>https://orcid.org/0000-0002-7585-4348</orcidid><orcidid>https://orcid.org/0000-0001-9653-0468</orcidid></search><sort><creationdate>202201</creationdate><title>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</title><author>Andrade Balbi, Verena ; Artur Silva, Clovis ; Nascimento Pedrosa, Tatiana ; Maria Rodrigues Pereira, Rosa ; Maria de Arruda Campos, Lucia ; Pires Leon, Elaine ; Duarte, Nilo ; Melechco Carvalho, Valdemir ; Gofinet Pasoto, Sandra ; Cordeiro do Rosário, Debora ; Kolachinski Brandao, Leticia ; I Brunner, Hermine ; Bonfá, Eloisa ; Emi Aikawa, Nadia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Blood levels</topic><topic>Children</topic><topic>Chromatography, Liquid</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Hydroxychloroquine - blood</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Liquid chromatography</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus nephritis</topic><topic>Lupus Nephritis - diagnosis</topic><topic>Lupus Nephritis - drug therapy</topic><topic>Mass spectroscopy</topic><topic>Morbidity</topic><topic>Nephritis</topic><topic>Prednisone</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andrade Balbi, Verena</creatorcontrib><creatorcontrib>Artur Silva, Clovis</creatorcontrib><creatorcontrib>Nascimento Pedrosa, Tatiana</creatorcontrib><creatorcontrib>Maria Rodrigues Pereira, Rosa</creatorcontrib><creatorcontrib>Maria de Arruda Campos, Lucia</creatorcontrib><creatorcontrib>Pires Leon, Elaine</creatorcontrib><creatorcontrib>Duarte, Nilo</creatorcontrib><creatorcontrib>Melechco Carvalho, Valdemir</creatorcontrib><creatorcontrib>Gofinet Pasoto, Sandra</creatorcontrib><creatorcontrib>Cordeiro do Rosário, Debora</creatorcontrib><creatorcontrib>Kolachinski Brandao, Leticia</creatorcontrib><creatorcontrib>I Brunner, Hermine</creatorcontrib><creatorcontrib>Bonfá, Eloisa</creatorcontrib><creatorcontrib>Emi Aikawa, Nadia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andrade Balbi, Verena</au><au>Artur Silva, Clovis</au><au>Nascimento Pedrosa, Tatiana</au><au>Maria Rodrigues Pereira, Rosa</au><au>Maria de Arruda Campos, Lucia</au><au>Pires Leon, Elaine</au><au>Duarte, Nilo</au><au>Melechco Carvalho, Valdemir</au><au>Gofinet Pasoto, Sandra</au><au>Cordeiro do Rosário, Debora</au><au>Kolachinski Brandao, Leticia</au><au>I Brunner, Hermine</au><au>Bonfá, Eloisa</au><au>Emi Aikawa, Nadia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2022-01</date><risdate>2022</risdate><volume>31</volume><issue>1</issue><spage>97</spage><epage>104</epage><pages>97-104</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Objective Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN). Methods Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry. Results There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013). Conclusions We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>34965782</pmid><doi>10.1177/09612033211062515</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3723-5028</orcidid><orcidid>https://orcid.org/0000-0001-9250-6508</orcidid><orcidid>https://orcid.org/0000-0002-0520-4681</orcidid><orcidid>https://orcid.org/0000-0002-7585-4348</orcidid><orcidid>https://orcid.org/0000-0001-9653-0468</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0961-2033
ispartof Lupus, 2022-01, Vol.31 (1), p.97-104
issn 0961-2033
1477-0962
language eng
recordid cdi_proquest_miscellaneous_2615476923
source MEDLINE; SAGE Complete
subjects Adult
Antirheumatic Agents - therapeutic use
Blood levels
Children
Chromatography, Liquid
Humans
Hydroxychloroquine
Hydroxychloroquine - blood
Hydroxychloroquine - therapeutic use
Liquid chromatography
Lupus
Lupus Erythematosus, Systemic - drug therapy
Lupus nephritis
Lupus Nephritis - diagnosis
Lupus Nephritis - drug therapy
Mass spectroscopy
Morbidity
Nephritis
Prednisone
Systemic lupus erythematosus
title Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A26%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hydroxychloroquine%20blood%20levels%20predicts%20flare%20in%20childhood-onset%20lupus%20nephritis&rft.jtitle=Lupus&rft.au=Andrade%20Balbi,%20Verena&rft.date=2022-01&rft.volume=31&rft.issue=1&rft.spage=97&rft.epage=104&rft.pages=97-104&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/09612033211062515&rft_dat=%3Cproquest_cross%3E2615476923%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622764267&rft_id=info:pmid/34965782&rft_sage_id=10.1177_09612033211062515&rfr_iscdi=true